Modified Ketogenic Diet in Patients With McArdle Disease Part B
Odified Ketogenic Diet in Patients With McArdle Disease Part B - a Placebo-controlled, Cross-over Study
Odified Ketogenic Diet in Patients With McArdle Disease Part B - a Placebo-controlled, Cross-over Study
Sponsor study identifier
interventional
20
2 countries
2
Study Start
August 3, 2019
Actual (reported)Primary Completion
October 1, 2022
Actual (reported)Study Completion
December 1, 2022
Actual (reported)McArdle disease, glycogen storage disease type V, is a rare metabolic disease. Affected individuals are unable to utilize sugar stored as glycogen in muscle. Investigators hypothesize that a modified ketogenic diet could be a potential treatment option, by providing ketones as alternative fuel substrates for working muscle. This blinded, placebo-controlled, cross-over study will investigate the potential effects of an optimal modified ketogenic diet found in part A (75% fat, 15%protein, 10%carbohydrates) in patients with McArdle disease compared with a healthy balanced placebo diet (\>100grams of carbohydrates per day).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 1, 2022
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 12, 2018
Actual (reported)August 3, 2019
Actual (reported)August 5, 2019
Actual (reported)October 1, 2022
Actual (reported)December 1, 2022
Actual (reported)Change in mean heart rate
Change in mean heart rate (bpm) during constant load cycling exercise (30 minute submaximal cycle test). Heart rate will be measured every minute during the cycle test at all visits.
At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks)
Compliance
up 12 weeks
Change in Indirect calorimetry
At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks)
Change in self-rated daily function scores
At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks)
Change in self-rated fatigue
At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks)
Change in blood ketones
At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks)
A modified ketogenic diet (with the composition found in the pilot study, 75%fat, 15% protein, 10% carbohydrates)
A placebo diet (over 100 g of carbohydrates per day)
Modified ketogenic diet
Placebo diet
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Copenhagen Neuromuscular Center, Rigshospitalet
Copenhagen, Denmark
National Hospital for Neurology and neurosurgery
London, United Kingdom
Lokken N, Nielsen MR, Stemmerik MG, Ellerton C, Revsbech KL, Macrae M, Slipsager A, Krett B, Beha GH, Emanuelsson F, van Hall G, Quinlivan R, Vissing J. Can a modified ketogenic diet be a nutritional strategy for patients with McArdle disease? Results from a randomized, single-blind, placebo-controlled, cross-over study. Clin Nutr. 2023 Nov;42(11):2124-2137. doi: 10.1016/j.clnu.2023.09.006. Epub 2023 Sep 20.
20 participants (actual enrollment reported by the registry).
First Submitted
December 12, 2018
First Posted
August 5, 2019
Study Start
A Study of the Safety of REN001 in Patients With McArdle Disease
Contact the study team to confirm eligibility.
August 3, 2019
Actual (reported)Primary Completion
October 1, 2022
Actual (reported)Study Completion
December 1, 2022
Actual (reported)Last Updated
February 13, 2023
Record last verified: 2023-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: